LifeVantage Announces Financial Results for the First Quarter Fiscal 2027
Lower expenses did not offset the revenue decline, although operating cash flow turned positive.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LifeVantage (Nasdaq: LFVN) reported fiscal first-quarter 2027 revenue of $37.1 million, down from the same quarter a year earlier. Revenue fell 22.0% in the quarter ended September 30, 2026. Americas revenue declined 22.2%, while Asia/Pacific & Europe revenue decreased 21.2%. Net loss was $0.2 million, or $0.02 per diluted share, versus net income of $2.2 million, or $0.17 per diluted share.
Gross margin fell to 75.4% from 79.5%, reflecting a MindBody inventory allowance and higher shipping and warehouse expenses. Adjusted earnings per diluted share declined to $0.05 from $0.18, and adjusted EBITDA fell to $1.9 million from $3.9 million. Operating cash flow turned positive at $0.5 million, versus $2.3 million used a year earlier. Cash totaled $13.7 million, down from $14.9 million at June 30, 2026, with no debt outstanding.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Minor pointOperating cash flow generated $0.5 million, versus $2.3 million used in the prior-year quarter.
- Minor pointCommissions and incentives decreased to $15.4 million, or 41.4% of revenue, from $20.7 million, or 43.5%.
- Minor pointSG&A expenses fell to $12.7 million from $14.9 million, although revenue share rose to 34.3% from 31.2%.
- Minor pointNo debt outstanding at September 30, 2026.
- Minor pointLoveBiome product sales partially offset revenue declines following the product line's October 2025 acquisition.
Negative
- Major pointRevenue fell 22.0% year over year to $37.1 million from $47.6 million.
- Moderate pointNet loss was $0.2 million, or $0.02 per diluted share, versus $2.2 million income, or $0.17.
- Moderate pointGross profit fell to $28.0 million from $37.8 million; margin declined to 75.4% from 79.5%.
- Moderate pointAdjusted EBITDA fell to $1.9 million from $3.9 million; revenue margin declined to 5.2% from 8.2%.
- Moderate pointActive independent consultants declined 16.7% year over year to 40,000 at September 30, 2026.
- Moderate pointActive customers declined 20.5% year over year to 58,000 at September 30, 2026.
9 minor points
- Minor pointAmericas revenue declined 22.2% year over year to $29.0 million.
- Minor pointAsia/Pacific & Europe revenue decreased 21.2% year over year to $8.2 million.
- Minor pointForeign currency reduced quarterly revenue by $0.4 million, or 0.8%.
- Minor pointMindBody inventory obsolescence allowance totaled $1.045 million in the quarter.
- Minor pointOperating loss was $0.1 million, versus operating income of $2.3 million a year earlier.
- Minor pointAdjusted operating income declined to $0.9 million from $2.5 million a year earlier.
- Minor pointAdjusted net income fell to $0.6 million, or $0.05 per diluted share, from $2.3 million, or $0.18.
- Minor pointMindBody GLP-1 System sales decreased, contributing to the quarterly revenue decline.
- Minor pointCash and cash equivalents declined to $13.7 million from $14.9 million at June 30, 2026.
News Explained
For the quarter ended
Details
Market move: LFVN -5.29% vs previous close. Q1 FY27 earnings report
On Nov 9, the day this news came out, the latest delayed price for LFVN is 5.29% below the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $5.01.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $37.1 million (-22.0% year over year)
- First quarter fiscal 2027; prior-year revenue was $47.6 million
- Diluted EPS
- -$0.02 vs. $0.17
- First quarter fiscal 2027 vs. first quarter fiscal 2026
- Adjusted diluted EPS
- $0.05 vs. $0.18
- First quarter fiscal 2027 vs. first quarter fiscal 2026
- Adjusted EBITDA
- $1.9 million vs. $3.9 million
- First quarter fiscal 2027 vs. first quarter fiscal 2026
- Gross margin
- 75.4% vs. 79.5%
- First quarter fiscal 2027 vs. prior-year period
- Cash from operations
- $0.5 million generated vs. $2.3 million used
- Three months ended September 30, 2026 vs. prior-year period
- Cash and debt
- $13.7 million cash; no debt outstanding
- September 30, 2026
Previous Earnings Reports
-
Revenue fell 23.1% year over year; diluted EPS and adjusted EBITDA were also lower.
-
Revenue declined 25.2%; the company expected fiscal 2026 results near the lower end of guidance.
-
Revenue fell 27.8% year over year, alongside lower earnings and a fiscal 2026 guidance range.
-
Revenue grew 0.7% year over year, with net income and adjusted EBITDA reported.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ebitda financial
non-gaap financial
inventory obsolescence financial
nutrigenomics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Nov. 09, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its quarter ended September 30, 2026.
First Quarter Fiscal 2027 Summary*:
- Revenue was
$37.1 million , a decrease of22.0% from the prior year period; - Revenue in the Americas decreased
22.2% , and revenue in Asia/Pacific & Europe decreased21.2% ; - Net loss per diluted share was
$0.02 , versus net income per diluted share of$0.17 a year ago; - Adjusted earnings per diluted share was
$0.05 , compared to$0.18 a year ago; and - Adjusted EBITDA was
$1.9 million compared to$3.9 million a year ago.
* All comparisons are on a year over year basis and compare the first quarter of fiscal 2027 to the first quarter of fiscal 2026, unless otherwise noted.
“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it,” said Terrence Moorehead, President and Chief Executive Officer. “Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates. At the same time, we are creating a more focused and efficient operating model and strengthening the underlying economics of the business. We have a lot of work to do, and building the company we envision will take time, but we have a differentiated foundation, a clear roadmap and a strong sense of urgency around execution. The actions we are taking are designed to build a stronger, more relevant LifeVantage and create sustainable long-term value for our shareholders.”
First Quarter Fiscal 2027 Results
For the first quarter ended September 30, 2026, the Company reported revenue of
Gross profit for the quarter was
Commissions and incentives expense for the quarter was
Selling, general and administrative (SG&A) expense for the quarter was
Operating loss for the quarter was
Net loss for the quarter was
Adjusted EBITDA was
Balance Sheet & Liquidity
The Company generated
Share Repurchase
During the quarter ended September 30, 2026, the Company did not repurchase any shares of its common stock. As of September 30, 2026, there was
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Monday, November 30, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13762997, or (412) 317-6671 from international locations, and entering confirmation code 13762997.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://investor.lifevantage.com/events-and-presentations. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, expected financial performance, including revenue margins, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contacts:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||||
| September 30, 2026 | June 30, 2026 | ||||||
| (In thousands, except per share data) | |||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 13,726 | $ | 14,920 | |||
| Accounts receivable | 1,806 | 2,990 | |||||
| Income tax receivable | 933 | 1,386 | |||||
| Inventory, net | 14,228 | 16,167 | |||||
| Prepaid expenses and other | 3,854 | 2,834 | |||||
| Total current assets | 34,547 | 38,297 | |||||
| Property and equipment, net | 8,058 | 7,310 | |||||
| Right-of-use assets | 6,364 | 6,715 | |||||
| Intangible assets, net | 2,930 | 3,058 | |||||
| Goodwill | 465 | 465 | |||||
| Deferred income tax asset | 6,195 | 5,629 | |||||
| Other long-term assets | 646 | 637 | |||||
| TOTAL ASSETS | $ | 59,205 | $ | 62,111 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 5,191 | $ | 5,156 | |||
| Commissions payable | 4,470 | 5,724 | |||||
| Lease liabilities | 1,921 | 1,935 | |||||
| Other accrued expenses | 6,512 | 7,412 | |||||
| Total current liabilities | 18,094 | 20,227 | |||||
| Long-term lease liabilities | 7,483 | 7,933 | |||||
| Other long-term liabilities | 370 | 362 | |||||
| Total liabilities | 25,947 | 28,522 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity | |||||||
| Preferred stock — par value | — | — | |||||
| Common stock — par value | 1 | 1 | |||||
| Additional paid-in capital | 139,255 | 138,924 | |||||
| Accumulated deficit | (104,286 | ) | (103,462 | ) | |||
| Accumulated other comprehensive loss | (1,712 | ) | (1,874 | ) | |||
| Total stockholders’ equity | 33,258 | 33,589 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 59,205 | $ | 62,111 | |||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | |||||||
| Three Months Ended September 30, | |||||||
| (unaudited) | |||||||
| 2026 | 2025 | ||||||
| (In thousands, except per share data) | |||||||
| Revenue, net | $ | 37,117 | $ | 47,561 | |||
| Cost of sales | 9,148 | 9,745 | |||||
| Gross profit | 27,969 | 37,816 | |||||
| Operating expenses: | |||||||
| Commissions and incentives | 15,380 | 20,695 | |||||
| Selling, general and administrative | 12,725 | 14,853 | |||||
| Total operating expenses | 28,105 | 35,548 | |||||
| Operating income (loss) | (136 | ) | 2,268 | ||||
| Other income (expense): | |||||||
| Interest income, net | 45 | 87 | |||||
| Other expense, net | (93 | ) | (114 | ) | |||
| Total other income (expense) | (48 | ) | (27 | ) | |||
| Income (loss) before income taxes | (184 | ) | 2,241 | ||||
| Income tax expense | (12 | ) | (86 | ) | |||
| Net income (loss) | $ | (196 | ) | $ | 2,155 | ||
| Net income (loss) per share: | |||||||
| Basic | $ | (0.02 | ) | $ | 0.17 | ||
| Diluted | $ | (0.02 | ) | $ | 0.17 | ||
| Weighted-average shares outstanding: | |||||||
| Basic | 12,464 | 12,398 | |||||
| Diluted | 12,464 | 12,946 | |||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
| Revenue by Region (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | |||||||||||||||
| (unaudited) | |||||||||||||||
| 2026 | 2025 | ||||||||||||||
| Americas | $ | 28,954 | 78.0 | % | $ | 37,197 | 78.2 | % | |||||||
| Asia/Pacific & Europe | 8,163 | 22.0 | % | 10,364 | 21.8 | % | |||||||||
| Total | $ | 37,117 | 100.0 | % | $ | 47,561 | 100.0 | % | |||||||
| Active Accounts (Unaudited) | |||||||||||||||||||||||
| As of September 30, | Change from Prior | Percent | |||||||||||||||||||||
| 2026 | 2025 | Year | Change | ||||||||||||||||||||
| Active Independent Consultants | |||||||||||||||||||||||
| Americas | 27,000 | 67.5 | % | 32,000 | 66.7 | % | (5,000 | ) | (15.6 | )% | |||||||||||||
| Asia/Pacific & Europe | 13,000 | 32.5 | % | 16,000 | 33.3 | % | (3,000 | ) | (18.8 | )% | |||||||||||||
| Total Active Independent Consultants | 40,000 | 100.0 | % | 48,000 | 100.0 | % | (8,000 | ) | (16.7 | )% | |||||||||||||
| Active Customers | |||||||||||||||||||||||
| Americas | 45,000 | 77.6 | % | 59,000 | 80.8 | % | (14,000 | ) | (23.7 | )% | |||||||||||||
| Asia/Pacific & Europe | 13,000 | 22.4 | % | 14,000 | 19.2 | % | (1,000 | ) | (7.1 | )% | |||||||||||||
| Total Active Customers | 58,000 | 100.0 | % | 73,000 | 100.0 | % | (15,000 | ) | (20.5 | )% | |||||||||||||
| Active Accounts | |||||||||||||||||||||||
| Americas | 72,000 | 73.5 | % | 91,000 | 75.2 | % | (19,000 | ) | (20.9 | )% | |||||||||||||
| Asia/Pacific & Europe | 26,000 | 26.5 | % | 30,000 | 24.8 | % | (4,000 | ) | (13.3 | )% | |||||||||||||
| Total Active Accounts | 98,000 | 100.0 | % | 121,000 | 100.0 | % | (23,000 | ) | (19.0 | )% | |||||||||||||
| (1) Active Independent Consultants have purchased product in the prior three months for retail or personal consumption. |
| (2) Active Customers have purchased product in the prior three months for personal consumption only. |
| (3) Total Active Accounts is the sum of Active Independent Consultant accounts and Active Customer accounts. |
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA (Unaudited) | |||||||
| Three Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| (In thousands) | |||||||
| GAAP Net income (loss) | $ | (196 | ) | $ | 2,155 | ||
| Interest income, net | (45 | ) | (87 | ) | |||
| Provision for income taxes | 12 | 86 | |||||
| Depreciation and amortization | 730 | 610 | |||||
| Non-GAAP EBITDA | 501 | 2,764 | |||||
| Adjustments: | |||||||
| Stock compensation expense | 306 | 826 | |||||
| Other expense (income), net | 93 | 114 | |||||
| Other adjustments(1) | 1,045 | 217 | |||||
| Total adjustments | 1,444 | 1,157 | |||||
| Non-GAAP Adjusted EBITDA | $ | 1,945 | $ | 3,921 | |||
| (1) Other adjustments breakout: | |||||||
| MB System allowance for inventory obsolescence | 1,045 | — | |||||
| Other nonrecurring expenses, net of credits | — | 217 | |||||
| Total adjustments | $ | 1,045 | $ | 217 | |||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS (Unaudited) | |||||||
| Three Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| (In thousands, except per share data) | |||||||
| GAAP Net income (loss) | $ | (196 | ) | $ | 2,155 | ||
| Adjustments: | |||||||
| MB System allowance for inventory obsolescence | 1,045 | — | |||||
| Other nonrecurring expenses, net of credits | — | 217 | |||||
| Tax impact of adjustments(1) | (261 | ) | (46 | ) | |||
| Total adjustments, net of tax | 784 | 171 | |||||
| Non-GAAP Net income: | $ | 588 | $ | 2,326 | |||
| September 30, 2026 | |||||||
| 2027 | 2026 | ||||||
| Diluted earnings per share, as reported | $ | (0.02 | ) | $ | 0.17 | ||
| Total adjustments, net of tax | 0.06 | 0.01 | |||||
| Diluted earnings per share, as adjusted(2) | $ | 0.05 | $ | 0.18 | |||
| (1) Tax impact is based on the estimated tax rate for the transition period ending December 31, 2026 and the fiscal year ended June 30, 2026. | |||||||
| (2) May not add due to rounding. | |||||||
| Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited) | |||||||
| Three Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| (In thousands, except percentage data) | |||||||
| Revenue, net | $ | 37,117 | $ | 47,561 | |||
| Cost of sales | 9,148 | 9,745 | |||||
| GAAP Gross profit | 27,969 | 37,816 | |||||
| GAAP Gross profit percentage | 75.4 | % | 79.5 | % | |||
| Adjustments: | |||||||
| MindBody GLP-1 System™ allowance for inventory obsolescence | 1,045 | — | |||||
| GAAP Gross profit | 29,014 | 37,816 | |||||
| GAAP Gross profit percentage | 78.2 | % | 79.5 | % | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were LifeVantage's fiscal first-quarter 2027 earnings results?
LifeVantage reported a $0.02 loss per diluted share, compared with earnings of $0.17 per diluted share a year earlier. Revenue declined 22.0% to $37.1 million for the quarter ended September 30, 2026. Adjusted earnings per diluted share were $0.05, compared with $0.18 a year earlier.
Why did LifeVantage's revenue decline in fiscal first-quarter 2027?
LifeVantage attributed the decline primarily to lower active accounts and lower MindBody GLP-1 System sales, with account declines reflecting the broader macro environment. Sales from the LoveBiome product line, acquired in October 2025, partially offset those declines.